"How effective is Tolebrutinib in delaying disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), and what is its impact on the rate of new or enlarging lesions on MRI scans?"

More Islam Abdullah El-Ghani Ghanem's questions See All
Similar questions and discussions